Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, discusses the role of antibody-based therapies in treating patients with myelodysplastic syndromes (MDS). Dr Brunner highlights the monoclonal antibodies magrolimab and sabatolimab, which are currently being evaluated in Phase III studies. Dr Brunner further suggests lenses for interpreting the data emerging from these studies and ways to apply this information for the maximum benefit in patients with high-risk MDS. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть